[The interferons: pharmacology, mechanism of action, tolerance and side effects] (Q78658378)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12481400%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

review article

1 reference

title

[The interferons: pharmacology, mechanism of action, tolerance and side effects] (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12481400%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

1 reference

P Arnaud

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12481400%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

publication date

1 November 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12481400%20AND%20SRC:MED&resulttype=core&format=json

Revue de Médecine Interne

15 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12481400%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

volume

23 Suppl 4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12481400%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

page(s)

449s-458s

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12481400%20AND%20SRC:MED&resulttype=core&format=json

Pegylation: a novel process for modifying pharmacokinetics

15 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2802%2900659-8

7 January 2021

Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2802%2900659-8

7 January 2021

Development of pegylated interferons for the treatment of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2802%2900659-8

7 January 2021

Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2802%2900659-8

7 January 2021

Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2802%2900659-8

7 January 2021

Interferon kinetics and adverse reactions after intravenous, intramuscular, and subcutaneous injection

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2802%2900659-8

7 January 2021

Use of peginterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2802%2900659-8

7 January 2021

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2802%2900659-8

7 January 2021

Endocrine and neurological adverse effects of the therapeutic interferons

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2802%2900659-8

7 January 2021

[Interferon-alpha and auto-immunity]

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2802%2900659-8

7 January 2021

10.1016/S0248-8663(02)00659-8

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12481400%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

1 reference